XTLB vs. EGRX, CLNN, DRRX, CASI, NBRV, CARM, KRON, OCUP, AADI, and LEXX
Should you be buying XTL Biopharmaceuticals stock or one of its competitors? The main competitors of XTL Biopharmaceuticals include Eagle Pharmaceuticals (EGRX), Clene (CLNN), DURECT (DRRX), CASI Pharmaceuticals (CASI), Nabriva Therapeutics (NBRV), Carisma Therapeutics (CARM), Kronos Bio (KRON), Ocuphire Pharma (OCUP), Aadi Bioscience (AADI), and Lexaria Bioscience (LEXX). These companies are all part of the "pharmaceutical preparations" industry.
XTL Biopharmaceuticals (NASDAQ:XTLB) and Eagle Pharmaceuticals (NASDAQ:EGRX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, community ranking, media sentiment, valuation, profitability and analyst recommendations.
Eagle Pharmaceuticals received 333 more outperform votes than XTL Biopharmaceuticals when rated by MarketBeat users. However, 71.82% of users gave XTL Biopharmaceuticals an outperform vote while only 70.31% of users gave Eagle Pharmaceuticals an outperform vote.
In the previous week, Eagle Pharmaceuticals had 2 more articles in the media than XTL Biopharmaceuticals. MarketBeat recorded 3 mentions for Eagle Pharmaceuticals and 1 mentions for XTL Biopharmaceuticals. Eagle Pharmaceuticals' average media sentiment score of 0.20 beat XTL Biopharmaceuticals' score of 0.00 indicating that Eagle Pharmaceuticals is being referred to more favorably in the news media.
Eagle Pharmaceuticals has higher revenue and earnings than XTL Biopharmaceuticals.
XTL Biopharmaceuticals has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500. Comparatively, Eagle Pharmaceuticals has a beta of 0.45, suggesting that its stock price is 55% less volatile than the S&P 500.
Eagle Pharmaceuticals has a consensus target price of $17.00, suggesting a potential upside of 358.22%. Given Eagle Pharmaceuticals' higher probable upside, analysts plainly believe Eagle Pharmaceuticals is more favorable than XTL Biopharmaceuticals.
Eagle Pharmaceuticals' return on equity of 0.00% beat XTL Biopharmaceuticals' return on equity.
4.4% of XTL Biopharmaceuticals shares are owned by institutional investors. Comparatively, 85.4% of Eagle Pharmaceuticals shares are owned by institutional investors. 29.0% of XTL Biopharmaceuticals shares are owned by company insiders. Comparatively, 28.9% of Eagle Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Summary
Eagle Pharmaceuticals beats XTL Biopharmaceuticals on 9 of the 12 factors compared between the two stocks.
Get XTL Biopharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for XTLB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding XTLB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
XTL Biopharmaceuticals Competitors List
Related Companies and Tools
